| CASE REPORT |
|
| Year : 2019 | Volume
: 40
| Issue : 4 | Page : 242-246 |
|
|
Panchakarma in autoimmune pancreatitis: A single-case study
Rajkala P Patil1, Panchakshari D Patil2, Anup B Thakar3
1 Department of Panchakarma, Central Ayurveda Research Institute for Cardiovascular Diseases, Punjabi Bagh, New Delhi, India
2 Publication Section, Central Council for Research in Ayurvedic Sciences, Janakpuri, New Delhi, India
3 Department of Panchakarma, Institute of Teaching and Research in Ayurveda, Jamnagar, Gujarat, India
Correspondence Address:
Rajkala P Patil
Central Ayurveda Research Institute for Cardiovascular Diseases (Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH), Road No. 66, Punjabi Bagh (W), New Delhi - 110 026
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ayu.AYU_15_20
|
|
|
Autoimmune pancreatitis (AIP) is the pancreatic manifestation of a systemic fibro-inflammatory disorder. AIP is a unique form of pancreatitis in which autoimmune mechanisms are suspected to be involved in the pathogenesis. AIP is a rare disorder, its exact cause is unknown, but it is thought to be caused by the body's immune system attacking the pancreas and it responds to steroid therapy only. In Ayurveda, although there is no synonym for AIP, but has a resemblance in clinical features of Grahani Dosha (derangement of duodenum and intestine). The cause of Grahani Dosha is Mandagni (hypofunctioning of Agni) and Panchakarma therapy increases Agni. As per Charaka Samhita, treatment for Grahani Dosha amongst the Panchakarma therapy is Virechana (therapeutic purgation) and Basti (medicated enema). The present case report is of a 30-year-old female, diagnosed as case of AIP with multisystem involvement with increased level of immunoglobulin G (IgG), glycosylated heamoglobin (HbA1c), cholesterol, triglycerides, low-density lipoprotein (LDL) and body mass index (BMI). The patient was on anticholinergic agents, antacids, levothyroxine, multivitamin along with iron and antihistamine drugs since 1 year, but with not much relief. Patient was treated with classical Virechana and Madhutailika Basti. It was observed after the completion of therapy, that there was decrease in IgG, HbA1c, S. cholesterol, S. triglyceride, low density lipoprotein (LDL) and body mass index (BMI). This shows that Virechana and Basti play a significant role in patient with AIP associated with other disorders.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
